P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE REDIRECTT-1 STUDY WITH EXTENDED FOLLOW-UP
P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE REDIRECTT-1 STUDY WITH EXTENDED FOLLOW-UP
J V Matous, Y. C. Cohen, H Quach, L Rosinol et al.
Journal
Haematologica
Topics
Multiple Myeloma Research and Treatments
article
P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE REDIRECTT-1 STUDY WITH EXTENDED FOLLOW-UP
J V Matous, Y. C. Cohen, H Quach, L Rosinol, S. Kumar, N. Au, DH Yoon, T. Henninger, E. Scott, J. Zhang, S. Atrash, K. Onodera, C. Maffucci, J.C. Ye, J. Zhou, H. Magen, P. Rodríguez-Otero, H. Chuah, M. Krevvata, M. Takamoto, S. Trudel, J. Richter, S.Z. Usmani, P. Thakkar, L. Huang, S. Raza, L. O’Rourke, C. Heuck, L. Pei, M. Festa, T. Ishida, M.P. Chu, E. Medvedova, M-V. Mateos, J. Lu, M. Gatt
article en
Abstract
No abstract available for this paper.
Publication Tag
HaematologicaVol. 111(s2)
Institutions
Ulsan College (KR), Alberta Health Services (CA), Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), Tel Aviv University (IL), Oregon Health & Science University (US), The University of Melbourne (AU), Universidad de Salamanca (ES), Hebrew University of Jerusalem (IL), Royal Perth Hospital (AU), Princess Margaret Cancer Centre (CA), University of Ulsan (KR), Tohoku University Hospital (JP), Mount Sinai Medical Center (US), Levine Cancer Institute (US), Japanese Red Cross Medical Center (JP), Hospital Clínic de Barcelona (ES), Colorado Blood Cancer Institute (US), Clinica Universidad de Navarra (ES), Johnson & Johnson (Israel) (IL), Mayo Clinic in Florida (US), University of Houston (US)